Augustine Therapeutics’ Post

Register for the FOP Drug Development Forum in June in Stockholm, Sweden (or virtually). With the first-ever treatment for FOP approved in select countries and five active FOP clinical trials, there is still an abundance of preclinical research with the potential to be translated into safe and effective new medicines. Molecules advancing drug discovery, advanced therapeutic modalities and new technologies must continually be explored for their potential to treat understudied signs and symptoms of FOP. The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Learn more and register: ifopa.org/2024_fop_ddf

The IFOPA is hosting the 6th FOP Drug Development Forum on June 26-28 in Stockholm, Sweden as well as virtually. The DDF features 12-minute talks grouped into five sessions: 1. Clinical Trials in FOP 2. Observational Research and Real-World Evidence 3. Drug Discovery and the ACVR1/ALK2 Receptor 4. Systems Biology Approaches to the Treatment of FOP 5. Untargeted Discovery in FOP Apply to do a platform presentation and/or a poster with unpublished data or data not published before January 1, 2023: https://lnkd.in/dfrq8sYC Deadline is February 19. May 10 is the submission deadline for late-breaking data (data published February-May 2024). The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options.

For an insightful webinar about organoids and how ACROBiosystems' organoid solutions revolutionize the pharmaceutical landscape, feel free to go register 👇

#MeetwithACRO [ACRO Event - US] 🌟 Exciting News! Join Us for an Insightful Webinar 🌟In this Teach Me in 10 episode, we're thrilled to welcome Rebecca Warfield, Ph.D., the Field Application Scientist at ACROBiosystems, as our esteemed speaker. Discover how ACROBiosystems' innovative solutions are revolutionizing the pharmaceutical landscape, expediting drug development processes. Organoids serve as indispensable tools, offering accurate disease representations. They advance drug screening, toxicity assessment, and personalized medicine initiatives. With organoids, researchers gain unprecedented insights, accelerating the translation of preclinical findings into clinically relevant applications. Check out the Webinar Registration Link here: https://lnkd.in/eGgzig6h Don't miss this opportunity to gain invaluable insights from Dr. Rebecca Warfield and discover how organoids are reshaping drug development. Register now! #ACROBiosystems #Webinar #Organoids #DrugDevelopment #Innovation

https://lnkd.in/e2p6SFgk 🚀 Exciting News Alert! 🚀   We're thrilled to announce the launch of the Liver Ring Trial, a groundbreaking collaboration between TissUse GmbH and ESQlabs GmbH (a computational model expert), UCB, a global biopharmaceutical company and initiators of the ring trial, and five other pharmaceuticals (Orion Corporation, Sanofi-Aventis Recherche & Développement, Technologie Servier France/Biologie Servier, AstraZeneca AB, and Boehringer Ingelheim), set to revolutionize drug safety assessment! 👉 Press Release: https://lnkd.in/e2p6SFgk Novel Liver Ring Trial Set to Revolutionize Drug Safety Assessment We're embarking on a mission to validate the reproducibility and accuracy of Liver Micro-Physiological Systems (MPS) in predicting drug-induced liver injury (DILI) and intrinsic clearance. This marks a paradigm shift in non-clinical drug assessment.  To validate a tool to be used for the evaluation of both drug safety and metabolism. "Our microfluidic platform is not just about simulating liver functions; it's about creating a more holistic organ-to-organ interaction, thereby offering a more accurate representation of human physiology," stated Dr. Reyk Horland, CEO at TissUse. With the guidance of regulatory bodies like the European Medicines Agency (EMA) and the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) of the European Commission’s Joint Research Centre (JRC), we aim to provide more confidence to use MPS data for regulatory submission and, ultimately, support decision making. Join us in shaping the future of drug safety assessment! #LiverRingTrial #DrugSafety #Innovation #PreclinicalResearch #NAMs #OrganOnChip

Antisense Oligonucleotide (ASO) deals continue last week with Novo - Cardior Pharma €1.025bn deal. However, lets dive deeper into the preclinical drug & clinical trial landscape. 🔵 Preclinical Drug Landscape: 67 biopharma developers operating at this early stage, representing 68% of all ASO drugs at this early stage. A staggering 38 ASO drugs have been disclosed in 2024 so far. 🔵 Clinical Trial Landscape: 428 trials across all stages. 8 have been added in 2024. DMD & SMA are the most common indications with 13% & 6% respectively. Interesting to see 15% at PIII which should yield more approvals soon! Planning your drug and trial strategy is key in this competitive space, Beacon RNA can simplify this complexity. #RNA #ASO #Oligo

[#Healthcare] The Nov Santé team announces an investment in Oncodesign Services, a leading French player in pharmaceutical pre-clinical research led by Fabrice Viviani, PhD, alongside Elyan Partners. 🔬 This transaction occurs in the context of the acquisition of the Dutch company ZoBio , first milestone in the transformation of Oncodesign Services into an integrated drug discovery CRO. 🔎 Oncodesign Services is a major player in its sector, with core strengths in bioanalysis focusing on oncology and immuno-inflammation, and an extensive range of services, including medicinal chemistry, pharmaco-imaging and molecular radiotherapy. Based in Dijon and Les Ulis, with nearly 230 people, Oncodesign generated sales of €44 million in 2023. 🗣 “The outsourcing of pharmaceutical research services is a global trend. Maintaining France's and Europe's leading players in this field is vital to our healthcare sovereignty. This means supporting scientific expertise in drug discovery, the first link in the healthcare chain. We are very proud to support Oncodesign Services in its ambition to become a key player in drug discovery.” Arnaud Vincent, Managing Director – Healthcare 📰 Read more: https://lnkd.in/eu-jcHPU   #research #science #DrugDiscovery #DrugDiscoveryTechnology #pharmacy #biotech #CRO #oncology Asnen Cassam-Chenaï Samantha Schwartz Hugo Pergher Simon Mauclair Olivier MILLET Jean-François Félix Maxence de Vienne Guillaume Vacherand Davide Giacometti

At this year's AACR Annual Meeting, Arvinas, a pioneer in PROTAC technology, sponsored a session titled "From Chemistry to Clinic," focusing on PROTAC and ADC technologies and the breakthroughs achieved by their combination. The presentation by Marcel Rieker, a scientist from Merck Germany, sparked widespread interest and discussion. His talk revolved around an exciting concept: combining two cutting-edge drug discovery fields, PROTAC and ADC, to explore a new strategy for delivering degraders to diseased cells. The PROTAC-ADCs (Antibody Drug Conjugates) and self-assembling PROxAb shuttles presented by Marcel Rieker at the AACR 2024 meeting represent a significant innovation of PROTAC technology in the field of drug delivery system design. Through this research, it was demonstrated how to enhance the selectivity and efficacy of drugs against specific targets, which is of great significance for cancer treatment. #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical

👑Royalty Pharma's expanding portfolio...buys in, to the tune of $525M, to the biotech ImmuNext for a cut of Sanofi's acquired MS Drug, frexalimab. 💰 This will yield the right to earn royalties and milestone payments from the autoimmune disease drug, on global sales up to $2B, on a 'tiered royalty structure' Frexalimab’s Potential and Sanofi’s #Strategy 📒 Mid-stage P3 results on this were published in NEJM "Sanofi plans to seek approval for the medicine in 2027, anticipating annual sales of over 5 billion euros (approximately $5.4 billion) and royalties through 2041" 📈 This investment highlights the potential benefits of frexalimab in the treatment of multiple sclerosis (MS) and Royalty Pharma's strategic approach to portfolio diversification. #RMS #MultipleSclerosis #Biotech #Innovation #Sanofi #RoyaltyPharma #Pharma #Healthcare

1 Week Until the Deadline: February 19. Apply to present at the FOP Drug Development Forum June 26-28 in Stockholm. Presentations can be made in person or virtually. The DDF features 12-minute "FOP Talks" grouped in sessions that cover learnings from clinical trials, observational research, and rational drug design. This year’s event includes a session on untargeted discovery in FOP. Apply to do a platform presentation and/or a poster with unpublished data or data not published before January 1, 2024: https://lnkd.in/dfrq8sYC The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Learn more and register: ifopa.org/2024_fop_ddf